Chronic Kidney Disease Drugs Market – Global Forecast to 2025

  • Product Code:
    RP-ID-10085461
  • Published Date:
    17 Jul 2021
  • Region:
    Global
  • Pages:
    84
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Pub-ID-15

Impact Analysis on the Growth of Market

Activating Probable Propositions Amidst COVID-19 Crisis

With things going haywire, we analyze key points to make sure that the businesses around the globe are completely prepared to tackle potential implications caused by COVID-19. Be it protecting employees, customers or the overall business operations, we ensure that the employers take the right decisions, make strategic investments and maintain a healthy work culture along with taking probable measures to minimize the financial loss. Know More

ccs

Market Overview:

Global Chronic Kidney Disease Drugs Market – Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025
[85 pages report] This market research report includes a detailed segmentation of the global chronic kidney disease drugs market by drug class (antihypertensives, antihyperlipidemics, erythropoiesis-stimulating agents (ESAs), diuretics, and others), by end-users (hospitals and specialty clinics), by regions (North America, Europe, Asia Pacific, and Rest of the World).
Overview of the Global Chronic Kidney Disease Drugs Market
Infoholic’s market research report predicts that the “Global Chronic Kidney Disease Drugs Market” will grow at a CAGR of 4.1% during the forecast period. The market has witnessed flat growth in the past few years and is sustaining only due to the steady rise in the incidence of renal disorders leading to chronic kidney disease, increasing incidences of cardiovascular and metabolism-related disorders, and growing geriatric population globally.

The growing market trend continues and is one of the increasingly accepted markets in many countries worldwide. Chronic kidney disease drugs manufacturers are focusing on obtaining funds and collaborating with universities to enlarge their R&D capabilities. A majority of the revenue is generated from the leading players in the market with dominant sales from AbbVie, Amgen, GlaxoSmithKline, Roche, and AstraZeneca.
According to Infoholic Research analysis, North America accounted for the largest share of the global chronic kidney disease drugs market in 2018. The US dominates the market owing to the presence of a majority of the chronic kidney disease drugs manufacturers in the region. However, the fastest growth rate is anticipated to be in the APAC region due to the large kidney disease patient population and increasing awareness about the disease.
By Drug Class:
• Antihypertensives
• Antihyperlipidemics
• Erythropoiesis-stimulating agents (ESAs)
• Diuretics
• Others
The antihypertensives segment occupied the largest share in 2018. Currently, KBP Biosciences and Medpace, Inc. are conducting Phase 2 randomized clinical trial on KBP-5074 for patients with moderate-to-severe chronic kidney disease and uncontrolled hypertension.
By End-users:
• Hospitals
• Specialty Clinics
In 2018, hospitals accounted for the maximum share, followed by specialty clinics, due to the availability of technologically-advanced diagnostic equipment for the early diagnosis of the condition.
By Regions:
• North America
• Europe
• APAC
• RoW
North America is dominant in the global chronic kidney disease drugs market, followed by Asia Pacific and Europe. The significant share of the North America market comes from the US due to the availability of good reimbursement policies.
Chronic Kidney Disease Drugs Market Research Competitive Analysis – The market is growing at a flat rate, with a single-digit CAGR during the forecast period. Various initiatives are taken by government establishments and market players to increase awareness among individuals. Campaigns are conducted globally to encourage people in adopting healthy lifestyles. Many countries are focusing on national programs to create disease awareness, prevention, and treatment options; for example, country-level national dialysis program, kidney disease education portals, launch of kidney-related disorder treatment funding initiatives, etc. Exhaustive pipeline for chronic kidney disease drugs is promising and is much required for future market growth. For example, ROXADUSTAT (HIF-PHI) by FibroGen is currently being studied in Phase-III clinical trials in the US, Europe, China, and Japan. Dapagliflozin by AstraZeneca is currently in phase III to evaluate the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease (Dapa-CKD).
Key Vendors:
• AbbVie Inc.
• Amgen Inc.
• GlaxoSmithKline plc
• F. Hoffmann-La Roche Ltd.
• AstraZeneca
Key Competitive Facts
• Increasing CKD incidence, aging population, promising repayment or reimbursement plans in few nations, and enormous R&D activities for the CKD drug development are the major factors driving the market growth.
• Cell therapy produces better results in the earlier stages of kidney disease and has been shown to eliminate or reduce the need for regular dialysis.
• Research is being conducted to study the potential of miRNA as effective biomarkers and therapeutic targets for CKD treatments.
Benefits – The report provides complete details about the sub-segments of the chronic kidney diseases drugs market. Through this report, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives toward the disease management in the upcoming years along with details of the existing pureplay companies and new players entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.
Key Takeaways:
• Understanding the potential market opportunity with precise market size and forecast data.
• A detailed market analysis focusing on the growth of chronic kidney diseases drugs industry.
• Factors influencing the growth of the chronic kidney disease drugs market.
• In-depth competitive analysis of dominant and pure-play vendors.
• Prediction analysis of the chronic kidney diseases drugs market in both developed and developing regions.
• Key insights related to major segments of the chronic kidney diseases drugs market.
• Latest market trend analysis impacting the buying behavior of the consumers.
Key Stakeholders
 


Geography Analysis:


The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

  • North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth Market Players Analys  & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Middle East and Africa  (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook

.

Table of Contents
1 Industry Outlook 8
1.1 Industry Overview 8
1.2 Total Addressable Market 9
2 Report Outline 11
2.1 Report Scope 11
2.2 Report Summary 11
2.3 Research Methodology 12
2.4 Report Assumptions 13
3 Market Snapshot 14
3.1 Market Definition – Infoholic Research 14
3.2 Segmented Addressable Market (SAM) 14
3.3 Industry Trends 15
3.4 Related Markets 16
3.4.1 Active pharmaceutical ingredients (APIs) 16
3.4.2 Over-the-counter drugs (OTC) 16
3.4.3 Human Insulin 17
4 Market Outlook 19
4.1 Market Segmentation 19
4.2 Porter 5 (Five) Forces 19
5 Market Characteristics 22
5.1 Market Dynamics 22
5.1.1 Drivers 23
5.1.1.1 High incidence of chronic kidney disease (CKD) 23
5.1.1.2 Rise in incidence of cardiovascular disorders and diabetes 23
5.1.1.3 Increase in global geriatric population 23
5.1.2 Restraints 24
5.1.2.1 Competition from biosimilars 24
5.1.2.2 Complex drug development process 25
5.1.3 Opportunities 25
5.1.3.1 Promising Drug Pipeline Chronic Kidney Disease 25
5.1.3.2 Market expansion opportunities in emerging nations 27
5.1.3.3 Novel therapeutic approaches such as cell therapy 27
5.1.4 DRO – Impact Analysis 28
5.2 Key Stakeholders 29
6 Drug Class: Market Size and Analysis 30
6.1 Overview 30
6.2 Anti-hypertensives 31
6.1 Anti - hyperlipidemic 32
6.2 Erythropoiesis-stimulating agents (ESAs) 33
6.3 Diuretics Drugs 35
6.4 Others 36
7 End Users: Market Size and Analysis 38
7.1 Overview 38
7.2 Hospitals 38
7.3 Specialty Clinic 39
8 Regions: Market Size and Analysis 40
8.1 Overview 40
8.2 North America 42
8.2.1 Overview 42
8.3 Europe 43
8.3.1 Overview 43
8.4 Asia Pacific 45
8.4.1 Overview 45
8.5 Rest of the World 46
8.5.1 Overview 46
9 Competitive Landscape 49
10 Vendors Profile 51
10.1 AbbVie Inc. 51
10.1.1 Overview 51
10.1.2 Geographic Presence 54
10.1.3 Business Focus 54
10.1.4 SWOT Analysis 55
10.1.5 Business Strategies 55
10.2 Amgen Inc. 56
10.2.1 Overview 56
10.2.2 Geographic Presence 59
10.2.3 Business Focus 59
10.2.4 SWOT Analysis 59
10.2.5 Business Strategies 60
10.3 GlaxoSmithKline plc 60
10.3.1 Overview 60
10.3.2 Geographic Presence 63
10.3.3 Business Focus 64
10.3.4 SWOT Analysis 64
10.3.5 Business Strategies 65
10.4 F. Hoffmann-La Roche Ltd. 66
10.4.1 Overview 66
10.4.2 Business Units 67
10.4.3 Geographic Revenue 68
10.4.4 Business Focus 69
10.4.5 SWOT Analysis 69
10.4.6 Business Strategies 70
10.5 Astra Zeneca PLC 71
10.5.1 Overview 71
10.5.2 Geographic Presence 75
10.5.3 Business Focus 75
10.5.4 SWOT Analysis 76
10.5.5 Business Strategies 76
11 Companies to Watch for 77
11.1 Pfizer Inc. 77
11.1.1 Overview 77
11.2 Sanofi 78
11.2.1 Overview 78
11.3 Teva Pharmaceutical Industries Ltd. 79
11.3.1 Overview 79
11.4 Johnson & Johnson 80
11.4.1 Overview 80
11.5 Keryx Biopharmaceuticals Inc 81
11.5.1 Overview 81
11.6 FibroGen Inc. 82
11.6.1 Overview 82
Annexure 84
 Acronyms 84

Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

AbbVie Inc.
Amgen Inc.
GlaxoSmithKline plc
Hoffmann-La Roche Ltd.
AstraZeneca

Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports